Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo

Newell, Pippa; Toffanin, Sara; Villanueva, Augusto; Chiang, Derek; Minguez, Beatriz; Cabellos, Laia; Savic, Radoslav; Hoshida, Yujin; Lim, Kiat; Melgar-Lesmes, Pedro; Yea, KEMAL; Peix, Judit; Deniz, Kemal; Fiel, M.; Thung, Swan; Alsinet, Clara; Tovar, Victoria; Mazzaferro, Vincenzo; Bruix, Jordi; Roayaie, Sasan; Schwartz, Myron; Friedman, Scott; Llovet, Josep

doi:10.1016/j.jhep.2009.03.028

Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo

Copy For Citation

Newell P., Toffanin S., Villanueva A., Chiang D. Y., Minguez B., Cabellos L., ...More

JOURNAL OF HEPATOLOGY, vol.51, no.4, pp.725-733, 2009 (SCI-Expanded)

Publication Type: Article / Article
Volume: 51 Issue: 4
Publication Date: 2009
Doi Number: 10.1016/j.jhep.2009.03.028
Journal Name: JOURNAL OF HEPATOLOGY
Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Page Numbers: pp.725-733
Keywords: Liver cancer, HCV, Signaling pathway, Molecular therapies, Ras, mTOR, PROMOTER HYPERMETHYLATION, MOLECULAR CLASSIFICATION, ABERRANT METHYLATION, SIGNALING PATHWAYS, HIGH-FREQUENCY, SUPPRESSOR, RASSF1A, GENE, NORE1A, INACTIVATION
Erciyes University Affiliated: Yes

Abstract

Background/Aims: The success of sorafenib in the treatment of advanced hepatocellular carcinoma (HCC) has focused interest on the role of Ras signaling in this malignancy. We investigated the molecular alterations of the Ras pathway in HCC and the antineoplastic effects of sorafenib in combination with rapamycin, an inhibitor of mTOR pathway, in experimental models.